A family history of malignancy is the only patient-specific factor associated with a significantly increased risk for cancer among patients with psoriatic disease treated with biologics vs topical ...
SAN CARLOS, Calif. and DALLAS, Oct. 23, 2025 /PRNewswire/ -- CAGE Bio Inc., a clinical-stage biotechnology company pioneering novel immunomodulatory therapies for dermatological diseases, today ...
Clinicians in England and Wales may soon have a new option for treating chronic hand eczema (CHE). The National Institute for Health and Care Excellence (NICE) has recommended delgocitinib (Anzupgo, ...
On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene ...
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of ...
Experts discuss the central role of patient education and the strategic use of topical therapies in managing atopic dermatitis (AD), emphasizing the need for clear communication, age-appropriate ...
Oct 3 (Reuters) - Rocket Pharmaceuticals (RCKT.O), opens new tab said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback